3rd Quarter - Report

TCH GROUP, LLC for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

S. 1298, F.Y. 2010 Homeland Security Appropriations, drug importation issues. Monitored appropriation process; S. 1406, F.Y. 2010 Agriculture Appropriations, FDA funding, importation, Monitored appropriation process; H.R. 2847, F.Y. 2010 Commerce, Justice, Science Appropriations, importation issues. Monitored appropriations process.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1406 (111th), S. 1298 (111th), H.R. 2847 (111th)

Copyright/Patent/Trademark CPT

H.R. 1260, Patent Reform Act of 2009: patent reform issues; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009: patent settlements; S. 369, Preserve Access to Affordable Generics Act: patent settlements; S. 515, Patent Reform Act of 2009: patent reform issues; S. 610, Patent Reform Act of 2009: patent reform issues; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1427 (111th), S. 726 (111th), H.R. 1260 (111th), H.R. 1706 (111th), S. 515 (111th), S. 610 (111th), H.R. 1548 (111th), S. 369 (111th)

Health Issues HCR

S.- America's Healthy Future Act. (Finance Committee Version); S. 1679- The Affordable Health Choices Act; H.R. 3200: America's Affordable Health Choices Act of 2009; H.R. 1298, Pharmaceutical Market Access and Drug Safety Act of 2009: importation; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics; H.R. 2502, Comparative Effectiveness Research Act of 2009: comparative effectiveness; S. 488, Access to Cancer Clinical Trials Act of 2009, access to clinical trials; S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009: importation; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics; S. 1142, Informed Health Care Decision Making Act: drug labeling; S. 1213, Patient-Centered Outcomes and Research Act of 2009: comparative effectiveness; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009: importation; S. 1679, Affordable Health Choices Act: health reform, regulatory pathway for follow-on biologics, 340B program issues; H.R. 759, Food and Drug Administration Globalization Act, 2009: import safety; S. 623, Access to Life-Saving Medicine Act; Follow-on biologics

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 759 (111th), H.R. 1548 (111th), H.R. 3200 (111th), H.R. 1298 (111th), S. 1232 (111th), S. 623 (111th), S. 726 (111th), S. 1213 (111th), S. 525 (111th), S. 488 (111th), S. 1142 (111th), S. 1679 (111th), H.R. 1427 (111th), H.R. 2502 (111th)

Medicare/Medicaid MMM

S. 301, Physician Payments Sunshine Act of 2009: transparency issues; S. 330, Medicare Prescription Drug Savings and Choice Act: Part D issues; S. 458, False Claims Act Clarification Act of 2009: liability issues; S. 1110, Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009: Medicare payment issues; Health care reform issues, Senate Finance Committee options papers; H.R. 1788, False Claims Act of 2009; H.R. 684, Medicare Prescription Drug Cost Equalization Act, Part D issues

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 330 (111th), H.R. 684 (111th), S. 301 (111th), S. 458 (111th), H.R. 1788 (111th), S. 1110 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.